LPL Financial LLC Has $162.65 Million Stock Position in Boston Scientific Corporation $BSX

LPL Financial LLC grew its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 2.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,705,827 shares of the medical equipment provider’s stock after purchasing an additional 34,717 shares during the quarter. LPL Financial LLC’s holdings in Boston Scientific were worth $162,651,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in Boston Scientific by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after purchasing an additional 1,115,337 shares during the period. Rathbones Group PLC boosted its stake in Boston Scientific by 20.9% in the 4th quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock valued at $263,133,000 after purchasing an additional 477,680 shares during the period. Tounjian Advisory Partners LLC bought a new stake in Boston Scientific in the 4th quarter valued at $1,477,000. Waycross Partners LLC bought a new stake in Boston Scientific in the 4th quarter valued at $2,384,000. Finally, Kepler Cheuvreux Suisse SA bought a new stake in Boston Scientific in the 3rd quarter valued at $26,955,000. 89.07% of the stock is currently owned by institutional investors.

Insider Transactions at Boston Scientific

In other news, Director Edward J. Ludwig bought 3,580 shares of the stock in a transaction on Wednesday, May 20th. The stock was acquired at an average price of $56.68 per share, with a total value of $202,914.40. Following the acquisition, the director directly owned 25,359 shares in the company, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David C. Habiger bought 2,250 shares of the stock in a transaction on Wednesday, May 20th. The stock was purchased at an average cost of $55.92 per share, with a total value of $125,820.00. Following the acquisition, the director owned 13,878 shares in the company, valued at approximately $776,057.76. This represents a 19.35% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders acquired 9,800 shares of company stock valued at $554,012. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Price Performance

Boston Scientific stock opened at $48.42 on Thursday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a 52 week low of $47.17 and a 52 week high of $109.50. The stock has a market capitalization of $71.98 billion, a P/E ratio of 20.26, a price-to-earnings-growth ratio of 0.92 and a beta of 0.56. The stock has a fifty day moving average of $56.99 and a 200-day moving average of $75.49.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same quarter in the previous year, the firm earned $0.75 EPS. Boston Scientific’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, sell-side analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has initiated a share repurchase program on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on BSX. Royal Bank Of Canada restated an “outperform” rating on shares of Boston Scientific in a research note on Thursday, May 28th. UBS Group cut their target price on Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a research report on Tuesday, March 17th. Needham & Company LLC reiterated a “buy” rating and set a $77.00 target price on shares of Boston Scientific in a research report on Monday, May 18th. Leerink Partners cut their target price on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a research report on Thursday, May 28th. Finally, Raymond James Financial reiterated an “outperform” rating and set a $88.00 target price (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and an average price target of $85.92.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.